Business
Helix BioPharma To Present at Biotech Showcase(TM) 2010 on January 13
Helix BioPharma To Present at Biotech Showcase(TM) 2010 on January 13
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\nJan. 7, 2010 (Canada NewsWire Group) -- AURORA, Ontario, Jan. 7 /CNW/ --Helix BioPharma Corp. (TSX, FSE: \"HBP\" / OTCQX: \"HXBPF\") today announced that John Docherty, president and chief operating officer, will present at Biotech Showcase 2010 at 9:40 a.m. PST on January 13, 2010 at the Marines' Memorial Club and Hotel in San Francisco. Mr. Docherty will provide an overview of the Company's leading product development programs L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation will be posted on the Company's website, www.helixbiopharma.com, on January 13, 2010.About Helix BioPharma Corp.Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol \"HBP\" and on the OTCQX International Market under the symbol \"HXBPF\". For further information contact:Investor Relations Media RelationsRobert Flamm, Ph.D. Ian StoneRusso Partners LLC Russo Partners LLCTel: (212) 845-4226 Tel: (619) 814-3510Email:[email protected] Fax: (619) 955-5318www.russopartnersllc.com Email: [email protected] News Release contains certain forward-looking statements and information (collectively, \"forward-looking statements\") regarding the Company's planned presentation at Biotech Showcase 2010 and the Company's product development initiatives. Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, the fact that the presentation and the posting of the slide show portion of the presentation on the Company's website are subject to change or cancellation without notice; Helix's need for additional future capital, which may not be available in a timely manner or at all; the need for additional research and development, the outcome of which is uncertain; and uncertainty whether L-DOS47 or Topical Interferon Alpha-2b, or any other product development initiatives, will be successfully developed or commercialized. See the Company's latest ...